|
Elenbecestat Trials in Early Alzheimer Disease Terminated for Poor Risk-Benefit Profile
|
|
Continuing an unfortunate trend, Eisai and Biogen recently announced that they will discontinue phase 3 clinical trials of elenbecestat, a BACE inhibitor intended for the treatment of early Alzheimer disease. |
|
Read more
|
|
|
| Understanding Cerebral Venous Thrombosis: Rare but Sometimes Fatal |
|
Cerebral venous thrombosis (CVT) is a rare cause of stroke, with an incidence of approximately 1.3 per 100,000 per year. There is a wide spectrum of signs and symptoms, such as headache, visual disturbances, focal neurologic deficits, seizures, and decreased consciousness. |
|
Read more
|
|
|
